Ten years of tamoxifen ups cancer survival rates

Ten years of tamoxifen ups cancer survival rates. Dec. 2012, NHS Choices [online]

http://www.nhs.uk/news/2012/12December/Pages/Ten-years-of-tamoxifen-ups-cancer-survival-rates.aspx

Tamoxifen is commonly offered alongside other breast cancer treatments and it is usually recommended that treatment with the drug continues for five years after other treatments have ended. This is because research has found that a long-term course of tamoxifen can reduce the risk of breast cancer returning (recurrence) and can also help prevent breast cancer deaths. The researchers thought that extended treatment for 10 years may offer further benefits. They did in fact find that cancer recurrence was lower in women receiving 10 years of treatment compared with women getting the standard five years of treatment.

"SIEF" - Simultaneous implant exchange with fat

"SIEF" - Simultaneous implant exchange with fat: A new option in revision breast implant surgery. Plastic & reconstructive surgery, Dec. 2012, Vol. 130(6), p.1187-96.

Del Vecchio, D.A.

http://journals.lww.com/plasreconsurg/Fulltext/2012/12000/_SIEF__Simultaneous_Implant_Exchange_with_Fat___A.4.aspx

A technique of implant exchange is reported using recipient-site preexpansion followed by autologous fat transplantation to the breast in 12 consecutive patients with breast implants who desired implant removal. 

Reduced incidence of breast cancer-related lymphedema following mastectomy and breast reconstruction versus mastectomy alone

Reduced incidence of breast cancer-related lymphedema following mastectomy and breast reconstruction versus mastectomy alone.  Plastic & reconstructive surgery, Dec. 2012, Vol. 130(6), p.1169-78.

Card, A., et al.

http://journals.lww.com/plasreconsurg/Abstract/2012/12000/Reduced_Incidence_of_Breast_Cancer_Related.1.aspx

As breast cancer survivorship has increased, so has an awareness of the morbidities associated with its treatment. The incidence of breast cancer–related lymphedema has been reported to be 8 to 30 percent in all breast cancer survivors.